Credit: mannKind. Furoscix ReadyFlow offers a rapid, outpatient alternative for acute fluid overload management in heart failure and chronic kidney disease. Furoscix ReadyFlow demonstrated a ...
Cancer progression within 36 months of combination therapy identified patients with overall survival of less than 2 years.
Retatrutide 12mg achieved up to 22.6% (55.8 lbs) mean weight loss at week 80, alongside marked improvements in ...
In a scientific statement, the association states that consuming caffeinated coffee linked to reduced risks for type 2 diabetes, heart disease, stroke, heart failure.
The oral RAS(ON) multi-selective inhibitor nearly doubled overall survival compared with investigator’s choice chemotherapy in the phase 3 RASolute 302 trial.
Lundbeck’s investigational oral orexin 2 receptor agonist gains Fast Track status, aiming to address underlying pathophysiology in patients with narcolepsy.
Phase 1/2 GOBLET trial results demonstrated a 30% ORR (median DOR: 15.5 months) in 2L+ SCAC and an ~29% ORR (median DOR: ~17 months) in 3L SCAC. The Food and Drug Administration (FDA) has granted Fast ...
Delaying JAK inhibitor initiation yielded higher early antibody responses; earlier initiation linked to earlier improvement in arthritis.
TG-C failed to demonstrate statistically significant improvements over placebo in pain (VAS) or function (WOMAC) at 12 months. Topline data were announced from the phase 3 ACTiVION-II trial evaluating ...
Jideytro is FDA-approved for adult patients with locally advanced or metastatic ROS1-positive NSCLC who received prior ROS1 TKI therapy.
In the CALIBRATE trial, 76% of encaleret-treated patients normalized both blood and urine calcium at week 24 vs 4% on standard of care, while 91% achieved intact PTH restoration.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results